Sanofi says tolebrutinib drug delayed progressive MS by 31%

FRANKFURT (Reuters) – Sanofi (NASDAQ:SNY) said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the disease by 31%, as the French drugmaker eyes a request for approval later this year.

The company said earlier this month that the late-stage trial with the drug candidate tolebrutinib was successful.